The current NEJM has a good piece on the death of the blockbuster drug. The threefold argument:
- It is ever-rarer for one drug to be the only one in its class. The average new drug in the 1970s enjoyed 10.2-years of market exclusivity, while that is now down to 1.2 years.
- Even with healthcare, not everyone can afford all prescription medications
- The blockbuster model relies on the proposition that one drug size fits all, which is less true than ever